Zena Therapeutics

Executive Summary

Zena Therapeutics is a preclinical-stage biotechnology company spun out of Rutgers University, dedicated to developing safer therapeutics for mental health and addiction disorders. The company's mission is to prevent overdose and withdrawal fatalities by creating medications with improved safety profiles. Its lead program focuses on a novel class of GABA-A receptor positive allosteric modulators (PAMs) designed to avoid fatal respiratory depression, a key limitation of existing benzodiazepines and other GABAergic drugs. By targeting anxiety and substance use disorders, Zena aims to address significant unmet needs in psychiatric care, where current treatments carry risks of abuse, tolerance, and respiratory depression. The company's innovative approach leverages structural insights into GABA-A receptor subtypes to enhance therapeutic efficacy while minimizing adverse effects. As a preclinical-stage company, Zena Therapeutics has not yet advanced to clinical trials, but its technology holds promise for transforming the treatment landscape for millions of patients with mental health and addiction conditions. The company is headquartered in Cambridge, Massachusetts, a hub for biotech innovation, and continues to progress its lead program toward IND-enabling studies and potential partnerships.

Upcoming Catalysts (preview)

• 2027Lead Program IND-Enabling Studies Initiation30% success
• 2026Series A Funding Round50% success
• 2026Preclinical Proof-of-Concept Data Readout40% success